Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Oncology > Online
NEWS & BUZZ   Open Access     Cite

RP1: The regulatory impasse of oncolytic virus therapy and the unmet needs in melanoma

  • 1.

    ImmVira Bioscience Inc, Suzhou 215000, China

  • 2.

    Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of GI Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China

  • 3.

    Virogin Biotech Ltd., Shenzhen 518000, China

  • 4.

    ViroMissile, Inc., California 92037, United States

More Information
The Innovation Oncology  https://doi.org/10.59717/j.xinn-oncol.2026.100032  |  Cite this article
    • FullText(HTML)
  • 加载中
    • Cited by

  • Cite this article:

    Zhou G., Xie T., Jia W., et al. (2026). RP1: The regulatory impasse of oncolytic virus therapy and the unmet needs in melanoma. The Innovation Oncology 1:100032. https://doi.org/10.59717/j.xinn-oncol.2026.100032
    Zhou G., Xie T., Jia W., et al. (2026). RP1: The regulatory impasse of oncolytic virus therapy and the unmet needs in melanoma. The Innovation Oncology 1:100032. https://doi.org/10.59717/j.xinn-oncol.2026.100032

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(15) PDF downloads(8)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Published articles are licensed under CC BY with copyright retained by the authors.
    All contents on this site: Copyright © 2026 INNOVATION PRESS. All rights are reserved.